Vaughan E Darracott
Rev Urol. 2003;5 Suppl 4(Suppl 4):S28-33.
Finasteride, a 5-alpha-reductase inhibitor, dramatically suppresses the production of dihydrotestosterone in men; thus, attention has turned to this agent for the treatment of benign prostatic hyperplasia (BPH). A number of randomized clinical trials have studied finasteride's effects on prostate size, BPH symptoms, flow rate, and prostate-specific antigen (PSA) level. Although the decrease in symptoms with finasteride therapy has been modest compared with more invasive treatments, its use has resulted in sustained reductions in prostatic volume and PSA level with minimal adverse effects. Fewer surgeries for BPH, as well as a decreased incidence of acute urinary retention, have also been seen with finasteride therapy. More research is needed to maximize the effectiveness of such medical therapy for BPH.
非那雄胺是一种5-α还原酶抑制剂，能显著抑制男性体内双氢睾酮的生成；因此，人们已将注意力转向该药物用于治疗良性前列腺增生（BPH）。多项随机临床试验研究了非那雄胺对前列腺大小、BPH症状、尿流率和前列腺特异性抗原（PSA）水平的影响。尽管与更具侵入性的治疗相比，非那雄胺治疗引起的症状减轻程度较小，但其使用已使前列腺体积和PSA水平持续降低，且副作用最小。非那雄胺治疗还使BPH手术数量减少，急性尿潴留的发生率也有所降低。需要进行更多研究以最大限度地提高这种治疗BPH的药物疗法的有效性。
